anti-Chemokine (C-C Motif) Ligand 13 (CCL13) Antikörper

Human Chemokine (C-C Motif) Ligand 13 (CCL13) Interaktionspartner

1. In plasma, but not CSF, the bivariate MCP4 (CCL13)/ MCP1(CCL2) ratio is ca. twofold elevated in PTSD patients compared with healthy controls.

2. CCL13 expression is significantly upregulated in human masticatory mucosa during wound healing

3. The reduction of circulating levels of MCP-4, eotaxin-3, and MIP-1beta could be one of the mechanisms by which bariatric surgery contributes to the reduction of cardiovascular risk in these patients.

4. CCL13 levels in serum and synovial fluid may serve as a biomarker for the progression of osteoarthritis.

5. identified 13 ADCC-activated genes. Six gene expression assays including 8 of the 13 genes (CCL3, CCL4/CCL4L1/CCL4L2, CD160, IFNG, NR4A3 and XCL1/XCL2) were analyzed in 127 kidney biopsies

6. CCL13 is an antimicrobial protein with bacteriocidal activity against E. coli.

7. Data suggest that CCL13 binds to several chemokine receptors (CCR1, CCR2, and CCR3), allowing CCL13 to elicit different effects on target cells of immune system. CCL13 is involved in pathology of chronic inflammatory/autoimmune diseases. [REVIEW]

8. MCP-4 and hsCRP may be the markers linking chronic inflammation in obesity and periodontal disease.

9. E(2) has adverse effects on the pathogenesis of RA as a result of unregulated cell death, increased TNF-alpha-induced MMP-3 production, and CCL13 overproduction, subsequently resulting in the disease progression of RA.

10. Data show that, for the small macrophages in COPD, increased transcript and protein levels for CCL2, CCL7, CCL13 and CCL22 with a more than 100-fold increase for CCL13 mRNA.

11. Findings suggest that the pro-atherogenic effects of CCR2 may not be restricted to interaction with MCP-1, but could also involve activation by MCP-4, being an inflammatory link between platelet and monocyte activation.

12. Data suggest that the monocyte chemoattractant protein-4 core promoter YY-1 binding motif is functional, and modulates the transcriptional regulation of the MCP-4 gene.

13. The study was undertaken to understand the relationship between the functional proteomics of receptor-Ck and developmental stages of human atherosclerotic aortic wall.

14. MCP-4 may be a critical molecule that links obesity and chronic inflammation.

15. Differential transcription occurring early in atopic dermatitis skin was indicated for CCL18, CCL13, IFNalpha2, PPARalpha and PPARgamma.

16. The Th2 cytokine IL-4 preferentially stimulated MCP-4 expression.

17. interferon-gamma with IL-1beta/TNF-alpha activates the production of CCL13 from chondrocytes in RA joints; secreted CCL13 enhances fibroblast-like synoviocyte proliferation by activating the extracellular signal-regulated MAP kinases cascade

18. TLR2, 3, 4 and 5 ligands, but not TLR7/8 or 9 ligands, synergized with IL-4 to induce the production of MCP-4 in nasal polyp fibroblasts.

19. CCL13 and HSPC159 mRNA expressions in PBMC are up-regulated specifically in MCNS patients during the nephrosis phase.

20. MMP-12 truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists